Hans E. Huber

faculty photo
Adjunct Professor of Pharmacology
Associate Director, Center for Targeted Therapeutics and Translational Nanomedicine, Perelman School of Medicine
Department: Systems Pharmacology and Translational Therapeutics

Contact information
213 Abbey Lane
Lansdale, PA
Education:
M.S. (Microbiology)
Swiss Federal Institute of Technology (ETH), Zürich, 1977.
Ph.D. (Biochemistry)
Swiss Federal Institute of Technology (ETH), Zürich , 1982.
Post-Graduate Training
Postdoctoral Fellow, Biozentrum, University of Basel, Switzerland , 1982-1984.
Research Fellow, Pharmacology, Harvard Medical School, Boston, 1985-1989.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Itmat Expertise

Targeted delivery of intracellular macromolecular therapeutics

Description of Other Expertise

Management of research collaborations and evaluation of licensing, investment and acquisition opportunities in the above areas.

Description of Research Expertise

Preclinical development of small molecules, antibodies and oligonucleotide therapeutics for oncology and other therapeutic areas. Targeted delivery of macromolecular therapeutics including nanoformulations and drug conjugates.

Selected Publications

Zhang N, Liu L. Dumitru C, Houston Cummings N, Cukan M, Jiang Y, Li Y, Li F, Mitchell T, Mallem M, Ou Y, Patel R, Vo K, Wang H, Burnina I, Choi B, Huber HE, Stadheim T, and Zha D: Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. mAbs 3: 289-298, 2011.

Cherrin C, Haskell K, Leander K, Watkins A, Bilodeau M, Hoffman J, Sanderson P, Hartman G, Prueksaritanont T, Jiang G, She QB, Rosen N, Jones D, and Huber HE: An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol. Ther. 9: 493-503, 2010.

Aste-Amézaga M, Lineberger JE, Arnold BA, Toner TJ, Huang L, Vitelli S, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR., Thoryk E, Tiyanont K, Stegmaier K, Roti G, Ross KN, Vo K, Gu M, Wang H, Wang F, Zhang N, Chastain M, Bett AJ, Aster JC, Blacklow SC, Audoly LP, and Huber HE: Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS ONE 5: e9094, 2010.

Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME, Buser CA, Walsh ES, Hamilton K, Schaber MD, Lobell RB, Tao W, Davide JP, Diehl RE, Abrams MT, South VJ, Huber HE, Torrent M, Prueksaritanont T, Li C, Slaughter DE, Mahan E, Fernandez-Metzler C, Yan Y, Kuo LC, Kohl NE, and Hartman GD: Kinesin spindle protein (KSP) inhibitors. J. Med. Chem. 51: 4239-4252, 2008.

She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, and Rosen N: Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3: e3065, 2008.

DeFeo-Jones D, Barnett SF, Hancock H, Haskell KM, Leander K, McAvoy E, Robinson R, Huber HE, and Jones RE: Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. 4: 271-279, 2005.

Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, Malinowski J, McAvoy EM, Nahas DD, Robinson R, and Huber HE: Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385: 399-408, 2005.

Yan Y, Sardana V, Xu B, Homnick C, Halczenko W, Buser CA, Hartman GD, Huber HE, and Kuo L: Inhibition of a mitotic motor protein: where, how, and conformational consequences. J. Mol. Biol. 335: 547-554, 2004.

Huber HE, Goodhart PJ, and Huang PS: Retinoblastoma protein reverses DNA bending by transcription factor E2F. J. Biol. Chem. 269: 6999-7005 1994.

Huber HE and Richardson CC: Processing of the primer for plus-strand DNA synthesis by HIV-1 reverse transcriptase. J. Biol. Chem. 265: 10565-10573 1990.

back to top
Last updated: 06/25/2023
The Trustees of the University of Pennsylvania